← Statins × lipids

TrialCirculation2012

Determinants of residual risk in secondary prevention patients treated with high- versus low-dose statin therapy: the Treating to New Targets (TNT) study.

Samia Mora et al.PubMed ↗Full text ↗Publisher ↗

It states no comparison between the randomised groups of NCT00327691. The report of the trial’s main result is not on the map, and the numbers here are shown and do not vote.

What moved togetherboth groups pooled, not the treatment’s effect

Correlation, not cause

Went with lower lipids

−18%−30% to −6%

Bigger than 4 in 10 on the map

As reported

HR 0.82, 95% CI 0.70–0.94

Correlation, not cause

Went with lower lipids

−33%−44% to −19%

Bigger than 7 in 10 on the map

As reported

HR 0.67, 95% CI 0.56–0.81

Correlation, not cause

Went with lower lipids

−9%−16% to −1%

Bigger than 2 in 10 on the map

As reported

HR 0.91, 95% CI 0.84–0.99

Three numbers in the abstract

the abstract, start to end

… risk were high-dose statin (aHR, 0.82; 95% CI, 0.70-0.94), aspirin use (aHR, 0.67; 95% CI, 0.56-0.81), and baseline apolipoprotein A-I (aHR, 0.91; 95% CI, 0.84-0.99 per 25 …

← favours treatmentfavours comparator →
could be chance
Lipids
HR 0.820.70–0.94
Lipids
HR 0.670.56–0.81
Lipids
HR 0.910.84–0.99
StatinsLipids
1 / 3

78 papers cite itlatest 60 shown

2012
…
2014
2015
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
this paperpooled ittrialcites it

The trial

NCT00327691phase 48,600 enrolled1998a later paper about it
Full record →Abstract, authors, funding and every citing paper · PMID 22461416